How big is Surgery Partners, Inc.?

As of Jun 18, Surgery Partners, Inc. has a market capitalization of $2.61 billion, with net sales of $3.17 billion and a net profit of -$12.1 million over the last four quarters.

Market Cap: As of Jun 18, Surgery Partners, Inc. has a market capitalization of 2,605.49 million, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Surgery Partners, Inc. reported net sales of 3,172.90 million and a net profit of -12.10 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,789.70 million and total assets of 8,008.90 million.

What does Surgery Partners, Inc. do?

Surgery Partners, Inc. is a small-cap healthcare services company in the hospital industry, with recent net sales of $776 million and a market cap of approximately $2.61 billion. Key financial metrics include a P/E ratio of 39.00 and a debt-to-equity ratio of 1.43.

Overview:<BR>Surgery Partners, Inc. is a healthcare services company operating in the hospital industry, categorized as a small-cap entity.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 776 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: 0 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 2,605.49 Million (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 39.00<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 1.43<BR>- Return on Equity: 4.40%<BR>- Price to Book: 1.50<BR><BR>Contact Details:<BR>- Address: 310 Seven Springs Way Ste 500, BRENTWOOD TN: 37027-5679<BR>- Tel: 1 615 2345900<BR>- Fax: 1 615 2345998<BR>- Website: http://www.surgerypartners.com/

Should I buy, sell or hold Surgery Partners, Inc.?

Who are in the management team of Surgery Partners, Inc.?

As of March 2022, the management team of Surgery Partners, Inc. includes Executive Chairman Wayne DeVeydt, CEO J. Eric Evans, and several independent directors: Clifford Adlerz, John Deane, Teresa DeLuca, Andrew Kaplan, and T. Devin O'Reilly. They oversee the company's operations and strategic direction.

As of March 2022, the management team of Surgery Partners, Inc. includes the following individuals:<BR><BR>- Mr. Wayne DeVeydt, who serves as the Executive Chairman of the Board.<BR>- Mr. J. Eric Evans, who is the Chief Executive Officer and a Director.<BR>- Mr. Clifford Adlerz, who is a Director.<BR>- Mr. John Deane, who is an Independent Director.<BR>- Dr. Teresa DeLuca, who is also an Independent Director.<BR>- Mr. Andrew Kaplan, who serves as an Independent Director.<BR>- Mr. T. Devin O'Reilly, who is another Independent Director.<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Is Surgery Partners, Inc. overvalued or undervalued?

As of August 6, 2024, Surgery Partners, Inc. is considered a risky investment due to its overvaluation indicated by a high P/E ratio of 39 compared to the peer average of 31.47, a lower ROE of 4.40% than the industry average, and significant underperformance against the S&P 500.

As of 6 August 2024, the valuation grade for Surgery Partners, Inc. has moved from fair to risky, indicating a shift in perception regarding its investment potential. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 39, which is significantly higher than the peer average of approximately 31.47 for comparable firms. Additionally, its EV to EBITDA ratio stands at 8.95, while peers like Universal Health Services, Inc. have a more favorable EV to EBITDA of 6.78, further highlighting the relative overvaluation.<BR><BR>In terms of profitability, Surgery Partners has a ROE of 4.40%, which is considerably lower than the industry average, suggesting inefficiencies in generating returns for shareholders. The stock has underperformed against the S&P 500, with a year-to-date return of 4.06% compared to the index's 12.22%, and a one-year return of -31.50% versus 17.14% for the S&P 500. This underperformance reinforces the notion that Surgery Partners, Inc. is currently overvalued in the market.

Is Surgery Partners, Inc. technically bullish or bearish?

As of October 24, 2025, Surgery Partners, Inc. has a mildly bearish trend influenced by mixed technical indicators, outperforming the S&P 500 recently but significantly underperforming over the long term.

As of 24 October 2025, the technical trend for Surgery Partners, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish MACD on the weekly timeframe and mildly bearish moving averages on the daily timeframe. The Bollinger Bands indicate a bullish signal on the weekly but a mildly bearish signal on the monthly, while the KST remains bearish across both timeframes. Dow Theory shows a mildly bullish stance on both weekly and monthly charts, and the OBV is mildly bullish weekly but bearish monthly.<BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 10.73% and 4.20% respectively, but it has significantly underperformed over longer periods, particularly the 1-year, 3-year, and 5-year horizons.